C V Asche

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. doi request reprint A review of diabetes treatment adherence and the association with clinical and economic outcomes
    Carl Asche
    Department of Pharmacotherapy, University of Utah, Salt Lake City, Utah, USA
    Clin Ther 33:74-109. 2011
  2. ncbi request reprint All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States
    Carl V Asche
    Department of Pharmacotherapy, University of Utah, Salt Lake City, UT 84108, USA
    J Manag Care Pharm 16:703-12. 2010
  3. doi request reprint Health economics and compliance of vials/syringes versus pen devices: a review of the evidence
    Carl V Asche
    Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, University of Utah College of Pharmacy, 421 Wakara Way, Salt Lake City, UT 84108, USA
    Diabetes Technol Ther 12:S101-8. 2010
  4. pmc Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA
    C Asche
    University of Utah College of Pharmacy, Salt Lake, UT, USA
    Osteoporos Int 21:1427-36. 2010
  5. pmc Assessment of COPD-related outcomes via a national electronic medical record database
    Carl Asche
    Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT 84108, USA
    Int J Chron Obstruct Pulmon Dis 3:323-6. 2008
  6. ncbi request reprint Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis
    Carl V Asche
    Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah 84108, USA
    Drugs Aging 25:611-22. 2008
  7. doi request reprint Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance
    Carl Asche
    Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, College of Pharmacy, University of Utah, 421 Wakara Way, Suite 208, Salt Lake City, UT 84108, USA
    J Antimicrob Chemother 61:1162-8. 2008
  8. ncbi request reprint The societal costs of low back pain: data published between 2001 and 2007
    Carl V Asche
    Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, University of Utah College of Pharmacy, 421 Wakara Way, Suite 208, Salt Lake City, UT 84108, USA
    J Pain Palliat Care Pharmacother 21:25-33. 2007
  9. ncbi request reprint Opinions regarding the value and use of the AMCP format still unknown
    Carl V Asche
    Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT 84108, USA
    J Manag Care Pharm 13:609-10. 2007
  10. ncbi request reprint Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes
    C V Asche
    Outcomes Research Center, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT 84108, USA
    Diabetes Obes Metab 10:638-45. 2008

Detail Information

Publications17

  1. doi request reprint A review of diabetes treatment adherence and the association with clinical and economic outcomes
    Carl Asche
    Department of Pharmacotherapy, University of Utah, Salt Lake City, Utah, USA
    Clin Ther 33:74-109. 2011
    ..However, it has been a challenge to quantify the relationship between adherence and outcomes such as glycemic control, disease-related events, hospitalizations, cost, and quality of life...
  2. ncbi request reprint All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States
    Carl V Asche
    Department of Pharmacotherapy, University of Utah, Salt Lake City, UT 84108, USA
    J Manag Care Pharm 16:703-12. 2010
    ..Whereas a number of studies have utilized a cross-sectional design to evaluate the costs associated with MS, no study has used a large administrative claims database to analyze the direct costs associated with newly diagnosed MS...
  3. doi request reprint Health economics and compliance of vials/syringes versus pen devices: a review of the evidence
    Carl V Asche
    Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, University of Utah College of Pharmacy, 421 Wakara Way, Salt Lake City, UT 84108, USA
    Diabetes Technol Ther 12:S101-8. 2010
    ..The goal of this review was to assess the state of the published literature on health economics and compliance of vials/syringes versus pen devices...
  4. pmc Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA
    C Asche
    University of Utah College of Pharmacy, Salt Lake, UT, USA
    Osteoporos Int 21:1427-36. 2010
    ..5 in the Geisinger Health System electronic health record database. Treatment was positively associated with age, oral corticosteroids, and smoking, and negatively associated with body mass index and bone mineral density scores...
  5. pmc Assessment of COPD-related outcomes via a national electronic medical record database
    Carl Asche
    Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT 84108, USA
    Int J Chron Obstruct Pulmon Dis 3:323-6. 2008
    ....
  6. ncbi request reprint Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis
    Carl V Asche
    Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah 84108, USA
    Drugs Aging 25:611-22. 2008
    ..To evaluate and compare the risk of adverse events (AEs) associated with the use of metformin, sulfonylureas and thiazolidinediones among geriatric patients in a usual care setting...
  7. doi request reprint Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance
    Carl Asche
    Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, College of Pharmacy, University of Utah, 421 Wakara Way, Suite 208, Salt Lake City, UT 84108, USA
    J Antimicrob Chemother 61:1162-8. 2008
    ..The aim is to quantify community-acquired pneumonia (CAP) treatment outcomes and costs from a managed care perspective by the level of macrolide resistance corresponding to the metropolitan statistical area (MSA) where patients lived...
  8. ncbi request reprint The societal costs of low back pain: data published between 2001 and 2007
    Carl V Asche
    Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, University of Utah College of Pharmacy, 421 Wakara Way, Suite 208, Salt Lake City, UT 84108, USA
    J Pain Palliat Care Pharmacother 21:25-33. 2007
    ..Newer, more costly agents such cyclooxengenase-2 selective nonsterioidal anti-inflammatory agents will increase drug costs as a portion of total costs, particularly if not used in accordance with treatment guidelines...
  9. ncbi request reprint Opinions regarding the value and use of the AMCP format still unknown
    Carl V Asche
    Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT 84108, USA
    J Manag Care Pharm 13:609-10. 2007
  10. ncbi request reprint Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes
    C V Asche
    Outcomes Research Center, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT 84108, USA
    Diabetes Obes Metab 10:638-45. 2008
    ..RESEARCH DESIGN and..
  11. ncbi request reprint Economic evaluations in pain management: principles and methods
    Carl V Asche
    Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, University of Utah College of Pharmacy, 421 Wakara Way, Suite 208, Salt Lake City, UT 84108, USA
    J Pain Palliat Care Pharmacother 20:15-23. 2006
    ....
  12. ncbi request reprint Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid
    Gary Oderda
    Department of Pharmacotherapy, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, 421 Wakara Way, Suite 208, Salt Lake City, UT 84108, USA
    Arch Gynecol Obstet 276:211-8. 2007
    ..To determine in an eligible Utah Medicaid population (1) medical and drug costs associated with treating uterine fibroids (UFs) and (2) the cost and incidence of hysterectomy complications...
  13. ncbi request reprint Explicit mention of outcomes in prescribing information
    Carl V Asche
    Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Suite 208, Salt Lake City, UT, 84108, USA
    J Pain Palliat Care Pharmacother 19:45-7. 2005
    ..Outcomes measures are increasingly mentioned in the approved labeling for drugs in several pharmacological-therapeutic categories. Examples of such labeling are presented...
  14. ncbi request reprint Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials
    Michael S Niederman
    Department of Medicine, Winthrop University Hospital, Minneola, NY 11501, USA
    Curr Med Res Opin 20:969-80. 2004
    ..To compare hospitalization rates among patients with community-acquired pneumonia (CAP) treated with oral telithromycin and clarithromycin, based on pooled data from two randomized, double-blind, multinational clinical trials...
  15. ncbi request reprint Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days
    Guy Tellier
    Zoom International Clinical Research Group, St Jerome, PQ, Canada
    Curr Med Res Opin 20:739-47. 2004
    ..To compare the impact on hospitalization rates and the clinical efficacy of oral telithromycin and clarithromycin treatment in patients with community-acquired pneumonia (CAP)...
  16. ncbi request reprint Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers
    Tyson W A Brooks
    St Louis College of Pharmacy, St Louis, Missouri 63110, USA
    Pharmacotherapy 27:684-90. 2007
    ..To determine the rates of hospitalizations and emergency department (ED) visits during cardioselective and nonselective beta-blocker therapy in patients with asthma and/or chronic obstructive pulmonary disease (COPD)...
  17. ncbi request reprint Has the cost-effectiveness of Xolair (omalizumab) been underestimated?
    Carl V Asche
    J Allergy Clin Immunol 115:1095; author reply 1095-6. 2005